The Alliance will provide a strong and unified voice for Myasthenia sufferers by generating more awareness of, and further interest in, these conditions. Through contact with Federal organisations, departments and individuals and by providing a point of contact for Australians from every state and territory, the Alliance provides a targeted forum with items of national importance. The Alliance will enhance the work done by the State Associations.
The drug Rituximab, otherwise known as MabThera, appears to be a more regularly considered treatment option for people with Myasthenia Gravis. Access to this drug varies greatly depending on each individual situation.